First and only bladder cancer immunotherapy ‘TECENTRIQ’ acquires approval from MFDS

Roche Korea(GM Matt Sause) announced acquisition of approval of TECENTRIQ(atezolizumab), the first and only anti-PDL1 cancer immunotherapy, on the 12^th of January as a secondary treatment from the Ministry of Food and Drug Safety(MFDS) for the treatment of people with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-based chemotherapy...